SIGNPATH PHARMA, INC. Patent Applications Rejected
14 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2023-07-31: Application 18263649; Invention TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS; Applicant Signpath Pharma, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2020-07-31: Application 16945195; Invention Suppression of Cytokine Release and Cytokine Storm; Applicant Signpath Pharma, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2019-12-02: Application 16700558; Invention Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR Channel; Applicant SignPath Pharma Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2019-10-22: Application 16660263; Invention TREATMENT FOR GLIOBLASTOMA; Applicant SignPath Pharma Inc.; Status Abandoned -- Failure to Respond to an Office Action.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2023-07-31 | 18263649 | TREATMENT FOR MALIGNANT PLEURAL EFFUSION IN HUMANS | Signpath Pharma, Inc. | Abandoned -- Failure to Respond to an Office Action | US20240180852A1 | Ashleigh Hocking Peter P. Sordillo Alexandra L. Farrall Sonja Klebe | Australia United States Australia Australia | SHOMER, ISAAC |
| 2020-07-31 | 16945195 | Suppression of Cytokine Release and Cytokine Storm | Signpath Pharma, Inc. | Abandoned -- Failure to Respond to an Office Action | US20200360300A1 | Peter P. Sordillo Lawrence Helson | United States United States | KRASS, FREDERICK F |
| 2019-12-02 | 16700558 | Liposomal Mitigation of Drug-Induced Inhibition of the Cardiac IKR Channel | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20200108056A1 | Lawrence Helson George M. Shopp Annie Bouchard | United States United States Canada | KISHORE, GOLLAMUDI S |
| 2019-10-22 | 16660263 | TREATMENT FOR GLIOBLASTOMA | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20200046652A1 | Laura A. Sordillo Peter Sordillo Lawrence Helson | United States United States United States | KISHORE, GOLLAMUDI S |
| 2019-09-05 | 16561195 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/ | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20190388422A1 | Lawrence Helson George M. Shopp Annie Bouchard Muhammed Majeed | United States United States Canada United States | VU, JAKE MINH |
| 2019-01-11 | 16246232 | Protective Effect of DMPC, DMPG, DMPC/ | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20190167585A1 | Lawrence Helson George M. Shopp Annie Bouchard Muhammed Majeed | United States United States Canada United States | VU, JAKE MINH |
| 2018-07-05 | 16028112 | COMPOSITIONS AND METHOD FOR REDUCING CARDIOTOXICITY | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20190008878A1 | Annie Bouchard | Canada | SZNAIDMAN, MARCOS L |
| 2018-06-13 | 16007283 | Liposomal Curcumin for Treatment of Diseases | SIGNPATH PHARMA INC. BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | Abandoned -- Failure to Respond to an Office Action | US20180318217A1 | Razelle Kurzrock Lan Li Kapil Mehta Bharat Bhushan Aggarwal Lawrence Helson | United States United States United States United States United States | SHOMER, ISAAC |
| 2017-02-22 | 15439405 | SPHINGOSINE KINASE INHIBITORS AND CERAMIDE FOR MAINTENANCE THERAPY OF GLIOBLASTOMA | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20170252311A1 | Lawrence Helson Laura A. Sordillo Peter Sordillo | United States United States United States | ANDERSON, JAMES D |
| 2016-03-28 | 15082708 | CURCUMIN FOR TREATING INTERVERTEBRAL DISC DISEASE | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20160287532A1 | Diana C. Sordillo Peter P. Sordillo Lawrence Helson | United States United States United States | PARAD, DENNIS J |
| 2015-09-11 | 14851966 | Method and System for Measuring the Pharmacokinetics of Liposomal Curcumin and its Metabolite Tetrahydrocurcumin | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20150377894A1 | Lawrence Helson | United States | PAPCIAK, SHARON M |
| 2015-05-29 | 14725624 | CURCUMIN-ER, A LIPOSOMAL-PLGA SUSTAINED RELEASE NANOCURCUMIN FOR MINIMIZING QT PROLONGATION FOR CANCER THERAPY | SignPath Pharma Inc. University of North Texas Health Science Center | Abandoned -- Failure to Respond to an Office Action | US20150258026A1 | Amalendu Prakash Ranjan Anindita Mukerjee Jamboor K. Vishwanatha Lawrence Helson | United States United States United States United States | DICKINSON, PAUL W |
| 2014-11-21 | 14550672 | INTRAVENOUS SYNTHETIC CURCUMIN (S-CURCUMIN) FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SignPath Pharma, Inc. | Abandoned -- Failure to Respond to an Office Action | US20150147385A1 | Lawrence Helson | United States | KISHORE, GOLLAMUDI S |
| 2014-04-30 | 14265669 | Intravenous Infusion of Curcumin and a Calcium Channel Blocker | SignPath Pharma Inc. | Abandoned -- Failure to Respond to an Office Action | US20140234402A1 | Lawrence Helson | United States | KISHORE, GOLLAMUDI S |